| Name | Hyvee Pharmacy 1177 |
|---|---|
| Organization Name | Hy Vee Inc |
| Location | 1920 Grant St, Faribault, Minnesota 55021 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (507) 334-1555 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
A low-cost device that Rice University bioengineering students invented to help premature babies breathe more easily will be rolled out to teaching hospitals in three African nations, thanks to a $400,000 award from pharmaceutical giant GlaxoSmithKline and London-based charity Save the Children. The technology, which is known as "bubble CPAP," earned the top prize in GSK and Save the Children's inaugural Healthcare Innovation Award program.
Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration (FDA) has accepted, for filing and review, the Biologics License Application (BLA) for ipilimumab for the treatment of adult patients with advanced melanoma who have been previously treated. The company also announced today that the application has been granted a priority review designation by the FDA.
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter ended March 31, 2010, and presented an update on recent clinical and corporate progress.
A new concept and policy framework published in PLOS NTDs outlines concrete steps for the global development community as it works to synthesize health goals with economic, environmental and social priorities.
› Verified 1 days ago
| NPI Number | 1053340711 |
| Organization Name | HY-VEE INC |
| Doing Business As | HY-VEE PHARMACY (1177) |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 1920 Grant St Nw, Faribault, MN 55021 |
| Phone Number | 507-334-1555 |
News Archive
A low-cost device that Rice University bioengineering students invented to help premature babies breathe more easily will be rolled out to teaching hospitals in three African nations, thanks to a $400,000 award from pharmaceutical giant GlaxoSmithKline and London-based charity Save the Children. The technology, which is known as "bubble CPAP," earned the top prize in GSK and Save the Children's inaugural Healthcare Innovation Award program.
Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration (FDA) has accepted, for filing and review, the Biologics License Application (BLA) for ipilimumab for the treatment of adult patients with advanced melanoma who have been previously treated. The company also announced today that the application has been granted a priority review designation by the FDA.
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter ended March 31, 2010, and presented an update on recent clinical and corporate progress.
A new concept and policy framework published in PLOS NTDs outlines concrete steps for the global development community as it works to synthesize health goals with economic, environmental and social priorities.
› Verified 1 days ago
News Archive
A low-cost device that Rice University bioengineering students invented to help premature babies breathe more easily will be rolled out to teaching hospitals in three African nations, thanks to a $400,000 award from pharmaceutical giant GlaxoSmithKline and London-based charity Save the Children. The technology, which is known as "bubble CPAP," earned the top prize in GSK and Save the Children's inaugural Healthcare Innovation Award program.
Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration (FDA) has accepted, for filing and review, the Biologics License Application (BLA) for ipilimumab for the treatment of adult patients with advanced melanoma who have been previously treated. The company also announced today that the application has been granted a priority review designation by the FDA.
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter ended March 31, 2010, and presented an update on recent clinical and corporate progress.
A new concept and policy framework published in PLOS NTDs outlines concrete steps for the global development community as it works to synthesize health goals with economic, environmental and social priorities.
› Verified 1 days ago
Sterling Drug Type: Community/Retail Pharmacy Location: 430 2nd Ave Nw, Faribault, Minnesota 55021 Phone: (507) 333-5464 | |
Bc Shoes Type: Medicare Supplier Location: 128 Central Ave N, Faribault, Minnesota 55021 Phone: (507) 334-7774 | |
Richie Eye Clinic Type: Medicare Supplier Location: 1575 20th St Nw, Faribault, Minnesota 55021 Phone: (507) 332-9900 | |
Hyvee Pharmacy 1177 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 1920 Grant St, Faribault, Minnesota 55021 Phone: (507) 334-1555 | |
Med City Mobility Llc Type: Durable Medical Equipment & Medical Supplies Supplier Location: 627 4th St Nw, Faribault, Minnesota 55021 Phone: (507) 334-2602 |